{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-277985","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2023-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.890375+00:00","generated_at":"2026-06-08T02:27:57.406464+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aeglea recasts FY2022 financials for 1-for-25 reverse split; going concern warning persists","bullets":["1-for-25 reverse stock split effective Sept 8, 2023; authorized shares cut from 500M to 20M.","Recast FY2022 net loss $83.8M ($24.86/share) on total revenue of $2.3M.","Accumulated deficit $425.6M as of Dec 31, 2022; cash & securities $57.3M.","Substantial doubt about going concern; cash expected to fund only into Q4 2023.","Auditor's opinion includes going concern emphasis paragraph."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-277985","json":"https://secwatch.observer/filing/0001193125-23-277985.json","markdown":"https://secwatch.observer/filing/0001193125-23-277985.md","text":"https://secwatch.observer/filing/0001193125-23-277985.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000119312523277985/0001193125-23-277985-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000119312523277985/d361815d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T02:27:57.406464+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}